HMA WGEO – Rapid Alert Form

Counterfeit or illegal product found in the illegal supply chain

Shaded area to be completed by the secretariat

Reference:		
Date:	Time:	Initials:
Please complete sections 1 to 5 *providing* as much information as possible.		

1. REPORTING PERSON

Name:	Position:
Organisation:	
Address:	
Telephone No:	Ext:
e-mail address:	

2. PRODUCT DETAILS

Product name: **Humira (*Adalimumabum*) 40 mg/0,8 ml, solution for injection, 2 pre-filled syringes, batch: 87392XD03, EAN 5909990005055**

Manufacturer:

Supplier:

Legal status: Banned ☐ Counterfeit ☐ Unlicensed ☐ **Stolen** ☒

Dosage form: **2 pre-filled syringes**

Strength: **40 mg/0,8 ml**

Batch / lot no: **87392XD03** Is batch number genuine: Yes ☒ No ☐

If yes to the above, advise batch destination country:

Expiry date:

Language of packaging: **Polish**

Date of discovery: **21-22 November 2018**

Details of discovery:

The Chief Pharmaceutical Inspector received information from the AbbVie Sp. z o.o. about theft of 12 packages of medicinal product Humira (batch mentioned above). Theft took place on November 21-22 2018 in the Polish pharmaceutical wholesaler: Poltraf Sp. z o.o. with office in Pass 05-870 Błonie, Stefana Batorego Str. 4. Product is owned by AbbVie Sp. z o.o. Up until this notification, the Company received from Poltraf Sp. z o.o. information on finding 6 packages of Humira. Recovered medicinal products will be disposed. Company has submitted a notice of the above crime to the District Prosecutor's Office.

Analysed: YES ☐ NO X

the lack of an active substance

3. DISTRUBUTION METHOD

Internet: YES ☐ / NO ☒

Internet:	Non internet, advise full details:
URL:	
Website address:	
Other details:	

Currency of payment:

Has product reached patients/consumers? **no information**

4. RISK TO PUBLIC HEALTH

Adverse reactions: YES ☐/ NO ☒

If yes, please advise details:

Medical assessment details:

5. NEED FOR PUBLICITY

Are you making a public statement? YES ☐ / NO ☒

Are you issuing a press release? YES☐ / NO ☒

Are you recalling product? YES ☐ / NO ☒

If yes to any of the above, when do you intend to take action?

6. DISSEMINATION

Are you content for this Rapid Alert to be shared outside WGEO membership?

YES ☒ / NO ☐ (please see below)

If yes, please specify which of the below you are content for this to be shared with (you may tick more than 1 box)

Law Enforcement ☒ Industry Security ☐ Trade Associations ☐

Traders ☐ Other ☐ Please specify

7. PHOTOGRAPH

If possible, please attach a photograph of the product.

...Głównego Inspektora Farmaceutycznego

Joanna Stajnik – Solska

Dyrektor Departamentu Nadzoru